YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

The Formulation and Bioavailability of Oral Sustained Release Sulindac Delivery System

설린닥의 경구용 지속성 제제설계 및 생체이용율

  • Published : 1997.02.01
Download PDF
⟨ Previous Next ⟩

Abstract

In order to design a 24 hr sustained release preparation of sulindac for oral administration, fast release pellet (FR), slow release pellet (SR) and two combined formulation (1 : 1 and 1 : 2) were prepared. The pharmacokinetic effect of such preparations has been evaluated using rabbits as a suitable in vivo model, and tested in man. Dose determination was carried out using curve fitting according to RSTPJP II program. In bioavailability test using rabbit, AUCs of sulindac in a few designed formulations were similar to each other. $C_{max}$- of RF and SR were 1.8 times and 1.2 times higher, respectively, compared to that of combined formulation (FR:SR=1:1). While plasma concentration of FR and SR decreased rapidly, that of combined formulation (FR:SR 1:1) lasted at the level close to $C_{max}$ for 24 hrs. Plasma concentration of sulfide form from the combined pellet(FR:SR=1:1) lasted for 24 hrs, and its AUC value was 1.4-fold, 2.7-fold. and 1.2-fold greater than FR pellet, SR pellet and combined pellet (FR:SR 1 : 2). Thus, the combined pellet of 1:1 ratio was found to be the most effective for oral sustained release formulation. Bioavailability test in human showed that AUC of sulfide from TSRP (1 : 1) was approximately 1.5 times greater than total AUC of Immbaron$^{\circledR}$ administered twice in a day. While $T_{max}$ of sulfide from lmmbaron$^{\circledR}$ was 4.33 +/- 1.37 hr (lst administration) and 3.33 ${pm}$ 0.82 hr (2nd administration), respectively, that of sulfide from TSRP increased to 7.17 ${pm}$ 2.86 hr. Plasma concentration of sulfide from TSRP was sustained at more, than 1.0 ${\mu}g{\cdot}$hr/ml until 24 hrs after one dose administration. In addition, TSRP may decrease local adverse reaction in the stomach, since plasma concentration of sulfide from the combined pellet was low within 2hrs in the stomach. In conclusion, it is suggested that TSRP formulation may be effective for oral 24 hr sustained release formulation of sulindac dosing 300 ~ 350mg once a day.

Keywords

References

  1. Fed. Amer. Soc. Exp. Biol. v.31 Synthesis of a new antiinflammatory agent cis-5-fluoro-2-methyl-1-[p-(methylsulfinyl)-benzyl-idenyl]indene-3-acetic acid. Shen, T. Y.;Witzel, B. E.;JOnes, H.;Linn, B. O.;McPhreson, J.;Greenwald, R.;Fordice, M.;Jacobs, A.
  2. Drugs v.16 Sulindac-a review of its pharmacological properties and therapeutic efficiency in rheumatic diseases Brogden, R. N.;Heel, R. C.;Speight, T. M.;Avery, G. S.
  3. Martindale Analgesics and Antiinflammatory Agents Reynolds, J. E. F.
  4. Antiinflammatory Analgesics 4c v.8 no.3 MIMS Korea: Antirheumatic Cocabo, S. C.;Pharm, B. S.;Kin, P. T.
  5. Amer. Pharm Associ. v.13 Analytical profiles of drug substances-Sulindac Plakogiannis, F. M.;McCauley, J. A.
  6. Scand. J. Rheumatol. v.8(Suppl) Sulindac vs phenylbutazone in the treatment of ankylosing spondylitis Godamski, M.;Singer-Bakker, H.;Braun, H. D.
  7. Scand. J. Rheumatol. v.8(Suppl) Controlled clinical study comparing a new antiinflammatory agent sulindac (MK-231) with aspirin in the treatment of rheumatoid arthritis Highton, T. C.;Jeremy, R.
  8. Scand. J. Rheumatol. v.8(Suppl) Evaluation of sulindac (MK-231) in acute gout Worthington, W. W.
  9. Amer. J. Gastroenterol. v.82 no.11 Gastroduodenal mucos and dyspeptic symptons in arthritis patients during chronic nonsteroidal antiinflammatory drug use Larkai, E. N.;Smith, J. L.;Lidsky, M. D.;Graham, D. Y.
  10. Dig. Dis. Sci. v.28 no.2 Gastric bleeding and gastric secretion with sulindac and naproxen Hut, J. N.;Smith, J. L.;Jiang, C. L.
  11. Clin. Pharmacol. Ther. v.24 The disposition of sulindac in man Duggan, D. E.;Hare, L. E.;Ditzler, C. A.;Lei, B. w.;Kwan, K. C.
  12. Clin. Pharmacol Ther. v.33 no.2 Enterohepatic circulation of sulindac and metabolites Dujovne, C. A.;pitterman, A.;Vincek, W. C.;Dobrinska, M. R.;Davies, R. O.;Duggan, D. E.
  13. J. Pharmacol. Exp. Ther. v.201 Identification of the biologically active form of sulindac Duggan, D. E.;Hooke, K. F.;Risely, E. A.;Shen, T. Y.;Van Arman, C. G.
  14. Drug Meta. Dispos. v.1 Physiologic disposition and metabolic fate of a new antiinflammatory agent, cis-5-fluoro-2-methyl-1-[p-(methylsulfinyl)-benzylidenyl]indene-3-a-cetic acid in the rat, dog, rhesus monkey and man Huker, H. B.;Stauffer, S. C.;White, S. D.;Rhodes, R. A.;Arrison, B. H.;Umbenhauer, E. R.;Bower, R. J.;McMahon, F. G.
  15. Eur. J. Rheumatol. Inflam. Kwan, K. C.;Duggan, D. E.;Van Arman, C. G.;Shen, T. Y.
  16. Biochem. Pharmacol. v.25 Enterohephatic circulation of indomethacin and its role in intestinal irritation Duggan, D. E.;Hooke, K. F.;Noll, R. M.;Kwan, K. C.
  17. Scand. J. Rheumatol. v.4 multi-clinic double-blind study comparing sulindac (MK-231) to aspirin and ibuprofen in outpatients with osteroarthritis Ballabio, C. B.;Colombo, B. A.
  18. Sustained and Controlled Release Drug Delivery System v.1 An overview of prolonged action drug dosage forms Ballard, G.;J. R. Robinson(ed.)
  19. A. Pharm. Tech Pub. v.29 The controlled release oral drug delivery opportunity, drug delivery systems, proceedings of an international conference Courson, J. D.
  20. Drug and the phramaceutical sciences v.6 Sustained and Controlled Release Drug Delivery Systems Robinson, J. R.
  21. In oral sustained release formulations : design and evaluation v.1 Silber B. M.;Cheung, W. K.;Yccobi, A.;A. Yacobi(ed.);E. Halperin-Walgega(ed.)
  22. Drug Dev. Ind. Pharm. v.9 Oral controlled drug administration. Pharmacokinetic considerations Welling, P. G.
  23. YAKHAK HOEJI(in press) Dissolution properties of oral sustained release sulindac dilivery system Rhee, G. J.;Suh, S. S.;Whang, S. S.
  24. J. Pharm. Sci. v.66 Analysis of sulindac and metabolites by combined isotope dilution radioimmunoassay Hare, L. E.;Ditter, C. A.;Hickens, M.;Rosedgay, A.;duggan, D. E.
  25. Pharmacologist. v.16 Analysis of cis-5-fluoro-2-methyl-1-[p-(methylsulfinyl)-benzylidenyl]indene-3-acetic acid and metabolites by combined isotope dilution radio immuno assay Hare, L. E.;Ditter, C. A.;Hickens, M.;Duggan, D. E.
  26. Anal. Biochem. v.95 Walker, R. W.;Gruber, V. F.;Rosenburg, A.;Wolf, F.;Avanden Heuvel, W.I.
  27. J. Chromatogr. v.416 no.2 Rapid high performance liquid chromatographic assay for the simultaneous analysis of nonsteroidal anti-inflammatory drugs in plasma Owen, S. G.;Roberts, M. S.;Friesen, W. T.
  28. J. Chromatogr. v.533 Liquid chromatography with amperometric detection for the determination of non-steroidal antiinflammatory drugs in plasma Kazemifard, A. G.;Moore, D. E.
  29. J. Pharm. Sci. v.73 Analytical methods for the determination of sulindac and mathabolites in plasma. urine, bile. and gastric fluid by liquid chromatography using ultraviolet detection Musson, D. G.;Vincek, W. C.;Constanzer, M. L.;Detty, T. E.
  30. J. Chromatogr. Sci. v.25 Liquid chromatographic determination of sulindac and metabolites in serum Clark, C. R.;McMillian, C. L.;Hoke, J. F.;Compagna, K. D.;Ravis, W. R.
  31. J. Chromatogr. v.20;414 no.1 High performance liquid chromatography of sulindac and its sulphone and sulfide methabolites in plasma Grgurinovich, N.
  32. J. Chromatogr. v.413 Analysis of sulindac and methabolites in plasma and urine by high performance liquid chromatography Stubbs, R. J.;Ng, L. L.;Entwistle, L. A.;Bayne, W. F.
  33. J. Chromatogr. v.257 no.2 Sample preparation by salts precipitation and quantitation by high performance liquid chromatography with UV detection of selected drugs in biological fluids Ng, L. L.
  34. Pharmacokinetics(2nd Ed.) Gibaldi, M.;Perrier, D.
  35. Biopharmaceutics and Clinical Pharmacokinetics(4th Ed.) Robert, E. N.
  36. Manual of pharmacologic calculations with computer programs(2nd Ed.) Tallarida, R. J.;Murray, B.